The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism

Although lung cancer patients harboring EGFR mutations benefit from treatment with EGFR‐tyrosine kinase inhibitors (EGFR‐TKI), most of them rapidly relapse. RHOB GTPase is a critical player in both lung carcinogenesis and the EGFR signaling pathway; therefore, we hypothesized that it could play a ro...

Descripción completa

Detalles Bibliográficos
Autores principales: Calvayrac, Olivier, Mazières, Julien, Figarol, Sarah, Marty‐Detraves, Claire, Raymond‐Letron, Isabelle, Bousquet, Emilie, Farella, Magali, Clermont‐Taranchon, Estelle, Milia, Julie, Rouquette, Isabelle, Guibert, Nicolas, Lusque, Amélie, Cadranel, Jacques, Mathiot, Nathalie, Savina, Ariel, Pradines, Anne, Favre, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286377/
https://www.ncbi.nlm.nih.gov/pubmed/28003335
http://dx.doi.org/10.15252/emmm.201606646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286377/
https://www.ncbi.nlm.nih.gov/pubmed/28003335
http://dx.doi.org/10.15252/emmm.201606646

Ejemplares similares